A Pilot Study of Cystic Volume Reduction by Foam Sclerotherapy in Autosomal Dominant Polycystic Kidney Disease
ADPKD is the most common inherited kidney disorder worldwide with a prevalence between 1:400 and 1:1000. Patients eventually develop kidney failure and require dialysis. Tolvaptan is the only treatment approved in Canada. Tolvaptan reduces the further growth of cysts but does not reduce the cyst burden.
Foam sclerotherapy is a novel treatment able to permanently shrink the size of cysts with minimal reported side effects. From 2014 to 2016, more than 60 patients underwent an experimental foam sclerotherapy procedure at Toronto General Hospital (TGH) with promising results!
Tolvaptan is not able to address the existing cyst burden in patients with autosomal dominant polycystic kidney disease (ADPKD). So the capstone goal is to validate the use of foam sclerotherapy as a treatment for ADPKD patients.
Capstone Advisory Committee:
PhD; Toronto General Research Institute
MD; Department of Medicine, Division of Nephrology; Toronto General Hospital, University Health Network; Professor of Medicine, University of Toronto
MD; Department of Medical Imaging; Toronto General Hospital, University Health Network; Assistant Professor, University of Toronto
TRP Faculty Lead: